Uncategorized
ASCO: Akeso’s VEGF/PD-1 boosts lung cancer survival, relieving pressure on US partner Summit
Analysts, investors and partner Summit Therapeutics had all been keenly awaiting the overall survival update, after previous data from Akeso’s HARMONi-6 trial left them wanting.